Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (191-200 of 627) with videos related to

Pageof 63
Sort By:
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trialMichael P Hudson, Paul W Armstrong, William W O'Neil, et al.
European Heart Journal|December 3, 2009
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarctionMichael C Tjandrawidjaja, Yuling Fu, Cynthia M Westerhout, et al.
Circulation|March 30, 2026
Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID TrialsSreekanth Vemulapalli, Karla Pena Guerra, Daniel Wojdyla, et al.
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
Diabetes, Obesity & Metabolism|October 10, 2015
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetesG Fulcher, D R Matthews, V Perkovic, et al.
Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Thrombosis Research|March 26, 2004
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levelsJacqueline Saw, Dean J Kereiakes, Kenneth W Mahaffey, et al.
Journal of Clinical Pharmacology|March 27, 2014
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AFI G Girgis, M R Patel, G R Peters, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 31, 2021
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital PerspectiveIvar S Jensen, Elizabeth Wu, Philip L Cyr, et al.
Pageof 63

Showing results (191-200 of 627) with videos related to

Sort By:
Pageof 63
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trialMichael P Hudson, Paul W Armstrong, William W O'Neil, et al.
European Heart Journal|December 3, 2009
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarctionMichael C Tjandrawidjaja, Yuling Fu, Cynthia M Westerhout, et al.
Circulation|March 30, 2026
Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID TrialsSreekanth Vemulapalli, Karla Pena Guerra, Daniel Wojdyla, et al.
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
Diabetes, Obesity & Metabolism|October 10, 2015
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetesG Fulcher, D R Matthews, V Perkovic, et al.
Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Thrombosis Research|March 26, 2004
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levelsJacqueline Saw, Dean J Kereiakes, Kenneth W Mahaffey, et al.
Journal of Clinical Pharmacology|March 27, 2014
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AFI G Girgis, M R Patel, G R Peters, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 31, 2021
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital PerspectiveIvar S Jensen, Elizabeth Wu, Philip L Cyr, et al.
Pageof 63